Home > Haematology > EHA 2021 > Leukaemia > Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia

Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia

Presented By
Prof. Susanne SauĂźele, Heidelberg University, Germany
Conference
EHA 2021
Trial
EURO-SKI
EURO-SKI evaluated the duration of treatment-free molecular remission and survival after cessation of treatment with tyrosine kinase inhibitors (TKIs) in the largest patient population studied to date. Three-year results of the EURO-SKI trial showed that approximately half of the participants with chronic myeloid leukaemia (CML) were in treatment-free remission. Treatment cessation has become a realistic therapy goal since the introduction of TKIs for the treatment of CML, with treatment-free remission being achievable in up to 55% of patients with deep molecular response (DMR). However, little is known about prognostic indicators of sustained treatment-free remission. Thus, the multicentre, open-label, uncontrolled EURO-SKI study (NCT01596114), aimed to define prognostic markers besides other goals. Prof. Susanne SauĂźele (Heidelberg University, Germany) pr...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on